Flag of the European Union EU Clinical Trials Register Help

Clinical trials for High frequency ventilation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    49 result(s) found for: High frequency ventilation. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2019-004720-38 Sponsor Protocol Number: LATE-REC-SURF Start Date*: 2020-12-21
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Effects of late surfactant treatment delivered after a recruitment maneuver on respiratory outcomes in extremely low gestational age newborns: a randomized controlled trial – LATE-REC-SURF Trial.
    Medical condition: Preterm infants still requiring mechanical ventilation at 7-10 days of life.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10076729 Very preterm infant LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001722-66 Sponsor Protocol Number: REP_COVID Start Date*: 2020-04-23
    Sponsor Name:Fundació Clínic per a la recerca Biomèdica
    Full Title: Plasma turnover in patients with COVID-19 disease and invasive mechanical ventilation: a randomized study
    Medical condition: coronavirus (covid-19) infection with respiratory failure requiring mechanical ventilation.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    21.1 10042613 - Surgical and medical procedures 10067221 Mechanical ventilation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001177-22 Sponsor Protocol Number: 02032021 Start Date*: 2021-04-26
    Sponsor Name:Copenhagen University Hospital, Hvidovre , Capital Region
    Full Title: Amantadine for COVID-19: A randomized, placebo controlled, double-blinded, clinical trial
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    23.0 10021881 - Infections and infestations 10084382 Coronavirus disease 2019 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001825-29 Sponsor Protocol Number: ANA-COVID-GEAS Start Date*: 2020-04-28
    Sponsor Name:NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET
    Full Title: CLINICAL TRIAL OF THE USE OF ANAKINRA (ANTI IL-1) IN CYTOKINE STORM SYNDROME (CSS) SECONDARY TO COVID-19
    Medical condition: Hyperinflammation and respiratory distress in patients with SARS- CoV-2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004198-41 Sponsor Protocol Number: UCDCRC/16/003 Start Date*: 2017-01-27
    Sponsor Name:University College Dublin
    Full Title: PROPHYLACTIC OROPHARYNGEAL SURFACTANT FOR PRETERM INFANTS: A RANDOMISED TRIAL (THE POPART TRIAL)
    Medical condition: Preterm Infants at risk of respiratory distress syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10054933 Neonatal respiratory distress syndrome prophylaxis PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) BE (Completed) SE (Completed) CZ (Completed) PT (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2015-002994-39 Sponsor Protocol Number: Cx611-0204 Start Date*: 2016-04-06
    Sponsor Name:TIGENIX, S.A.U.
    Full Title: A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for...
    Medical condition: Severe community-acquired bacterial pneumonia requiring mechanical ventilation and/or vasopressors.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) LT (Completed) GB (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001172-15 Sponsor Protocol Number: APN01-01-COVID19 Start Date*: 2020-04-08
    Sponsor Name:APEIRON Biologics AG
    Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19
    Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-004695-18 Sponsor Protocol Number: RES-Q-HR Start Date*: 2020-12-02
    Sponsor Name:Heinrich-Heine-University Düsseldorf
    Full Title: Reconvalescent plasma/Camostat mesylate early in Sars-CoV-2 Q-PCR positive high risk individuals
    Medical condition: The novel coronavirus designated SARS CoV-2, and the disease caused by this virus designated COVID-19. No treatment is available for early disease stages and non-hospitalized patients to date. This...
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    23.0 100000004848 10084442 SARS-CoV-2 PCR test positive LLT
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002369-32 Sponsor Protocol Number: 100-303 Start Date*: 2020-07-31
    Sponsor Name:Diffusion Pharmaceuticals Inc.
    Full Title: Open-label, pharmacokinetic, pharmacodynamic, ascending dose safety lead-in followed by a single-center, placebo-controlled, double-blind, adaptive, safety and efficacy, pilot study of Trans Sodium...
    Medical condition: COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001411-25 Sponsor Protocol Number: XPORT-COV-1001 Start Date*: 2020-05-18
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection
    Medical condition: Severe COVID-19 Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005227-37 Sponsor Protocol Number: OLT1177-10 Start Date*: 2021-03-03
    Sponsor Name:Olatec Therapeutics LLC
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of ...
    Medical condition: COVID-19, cytokine release syndrome
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000269-34 Sponsor Protocol Number: GC2010 Start Date*: 2021-03-20
    Sponsor Name:Grifols Therapeutics LLC
    Full Title: A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) versus Placebo in Asymptomatic Ambulatory...
    Medical condition: Subjects with laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by qualitative PCR (reverse transcriptase [RT]-PCR) that are asymptomathic
    Disease: Version SOC Term Classification Code Term Level
    23.0 10022891 - Investigations 10084271 SARS-CoV-2 test positive PT
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    23.0 100000004862 10084467 Asymptomatic SARS-CoV-2 infection LLT
    23.1 100000004862 10084529 2019 novel coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003125-39 Sponsor Protocol Number: TRI-08892 Start Date*: 2020-10-12
    Sponsor Name:Thrombosis Research Institute
    Full Title: Early thromboprophylaxis in COVID-19 (ETHIC trial): an open label, randomized phase IIIb trial of community-based prophylactic low-molecular-weight heparin (LMWH) versus standard of care (no enoxap...
    Medical condition: Confirmed diagnosis of SARS-CoV-2 with symptomatic COVID-19 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005059-35 Sponsor Protocol Number: TMP-2204-2021-47 Start Date*: 2022-01-25
    Sponsor Name:F4-Pharma GmbH i.G.
    Full Title: Potential of FX06 to improve disease severity in Acute Respiratory Distress Syndrome patients (Ixion 2.0)
    Medical condition: Acute Respiratory Distress Syndrome (ARDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003083 ARDS LLT
    24.0 10038738 - Respiratory, thoracic and mediastinal disorders 10085269 ARDS disease progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) LT (Trial now transitioned) PT (Prematurely Ended) IT (Prematurely Ended) NL (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003666-41 Sponsor Protocol Number: MEC2020-0078 Start Date*: 2020-04-21
    Sponsor Name:Erasmus MC University Medical Center
    Full Title: Doxapram versus placebo in preterm newborns: an international double blinded multicenter randomized controlled trial.
    Medical condition: Preterm infants are at high risk of respiratory failure due to immaturity of the respiratory system. Respiratory failure is caused by a comprised lung function and impaired control of breathing. Co...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077323 Infantile mixed apnea LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002011-21 Sponsor Protocol Number: MARACOVID Start Date*: 2020-06-02
    Sponsor Name:Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Leonor y Sureste (FIIB)
    Full Title: Bicentric, phase 2, randomized, open-label study to evaluate the efficacy and safety of maraviroc associated with standard treatment in hospitalized patients with pulmonary SARS-CoV-2 infection (CO...
    Medical condition: COVID-19 Pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002504-39 Sponsor Protocol Number: HERO-19 Start Date*: 2020-11-10
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Hamburg Edoxaban foR anticoagulation in COvid-19 study
    Medical condition: COVID-19 [Coronavirus disease 2019]
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001227-31 Sponsor Protocol Number: NISCI Start Date*: 2019-06-19
    Sponsor Name:University Zurich, University Hospital Balgrist, Spinal Cord Injury Center
    Full Title: Antibodies against Nogo-A to enhance plasticity, regeneration and functional recovery after acute spinal cord injury
    Medical condition: spinal cord injury
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10041554 Spinal cord injury cervical PT
    20.1 10022117 - Injury, poisoning and procedural complications 10041552 Spinal cord injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-001644-25 Sponsor Protocol Number: ACE-ID-201/D822FC00001 Start Date*: 2020-05-06
    Sponsor Name:Acerta Pharma B.V.
    Full Title: A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19
    Medical condition: Subjects with life-threatening COVID-19 symptoms
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018798-39 Sponsor Protocol Number: 19022010 Start Date*: 2010-05-03
    Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Abteilung für Endokrinologie
    Full Title: Correction of vitamin D deficiency in critically ill patients: a randomized, doulbe-blind, placebo-controlled trial
    Medical condition: Critically ill patients with vitamin D deficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 10:46:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA